Form 4: Nuvalent CFO Exercises Options, Sells Shares

Nuvalent Inc.'s Chief Financial Officer, Alexandra Balcom, exercised stock options and subsequently sold a portion of the acquired Class A Common Stock on October 1, 2025, under a pre-arranged trading plan.

Summary

• Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc. (NUVL), engaged in transactions involving the company's Class A Common Stock on October 1, 2025.
• Exercised stock options to acquire 16,787 shares at an exercise price of $6.89 per share.
• Exercised additional stock options to acquire 3,213 shares at an exercise price of $18.93 per share.
• Sold 19,030 shares of Class A Common Stock at a weighted average price of $85.43 per share, with prices ranging from $85.00 to $85.99.
• Sold an additional 970 shares of Class A Common Stock at a weighted average price of $86.37 per share, with prices ranging from $86.07 to $86.52.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
• Following these transactions, Alexandra Balcom directly beneficially owns 61,734 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine insider transaction, pre-planned under a 10b5-1 plan, indicating a structured approach to equity management rather than a reactive event. While it involves selling shares, the executive retains a significant holding, and the transaction itself does not provide new information about the company's operational performance or future prospects.

Positives

• The Chief Financial Officer realized significant gains by exercising stock options at substantially lower prices ($6.89 and $18.93) compared to the sale prices (weighted average of $85.43 and $86.37).
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to managing equity compensation rather than a reactive sale.

Negatives

• The sale of shares by a key executive, even under a 10b5-1 plan, could be perceived by some investors as a reduction in insider exposure, although a significant holding remains.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports a routine insider transaction for a publicly traded company. Such transactions are common for executives managing their equity compensation, particularly when executed under a Rule 10b5-1 plan, which allows insiders to set up a pre-arranged schedule for buying or selling shares to avoid accusations of trading on material non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction represents a realization of value by a key executive, which can be viewed positively as a reward for performance, but also as a reduction in direct insider ownership. However, the pre-planned nature mitigates immediate concerns.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports a pre-planned insider transaction by the CFO, involving the exercise of options and subsequent sale of shares. Such transactions, especially under a Rule 10b5-1 plan, are generally routine and do not typically signal a significant change in the company's fundamental outlook. While the executive realized substantial gains, a significant portion of their holdings remains. Therefore, this filing alone does not warrant a change in investment thesis, leading to a 'hold' recommendation.

Keywords

Nuvalent, NUVL, insider trading, stock options, CFO, Form 4, equity sale, 10b5-1 plan